Breaking News Instant updates and real-time market news.

DXCM

DexCom

$126.61

-3.86 (-2.96%)

, MDT

Medtronic

$98.51

-0.51 (-0.52%)

12:25
10/03/18
10/03
12:25
10/03/18
12:25

Piper Jaffray medical tech analysts to hold an analyst/industry conference call

Medical Technology Analyst McKim, along with a Nurse Practitioner at Massachusetts General Hospital (MGH), provide an update on diabetes including continuous Glucose Monitoring Systems and the competitive dynamics between Dexcom, Medtronic and Senseonics, pump competitive dynamics between Medtronic, Tandem Diabetes and Insulet, and overall tech adoption within the diabetic community on an Analyst/Industry conference call to be held on October 3 at 1 pm.

DXCM

DexCom

$126.61

-3.86 (-2.96%)

MDT

Medtronic

$98.51

-0.51 (-0.52%)

SENS

Senseonics

$4.26

-0.11 (-2.52%)

TNDM

TNDM

PODD

Insulet

$100.00

-1.91 (-1.87%)

  • 03

    Oct

  • 09

    Oct

  • 01

    Nov

  • 27

    Nov

DXCM DexCom
$126.61

-3.86 (-2.96%)

09/18/18
LEER
09/18/18
NO CHANGE
Target $170
LEER
Outperform
Leerink sees continued upside in shares of DexCom
Leerink analyst Danielle Antalffy continues to see upside in shares of DexCom after hosting investor meetings with management. The meetings reinforced the analyst's confidence that near-term guidance beatable and that the Street continue to underestimate both the pace of adoption ramp in the current Type 1 patient population and DexCom's "still-strong" competitive advantage even as new entrants come to market. She believes the company's 2018 guidance is "extremely conservative" and reiterates an Outperform rating on the shares with a $170 price target.
09/18/18
LSCM
09/18/18
NO CHANGE
Target $60
LSCM
Buy
Tandem Diabetes recent selloff a buying opportunity, says Lake Street
Lake Street analyst Brooks O'Neil views the recent pullback in shares of Tandem Diabetes (TNDM) as a buying opportunity. The analyst believes the stock is 'just getting going" and that the recent correction is healthy. The revolution underway in diabetes management today involves using innovative technology to monitor and adjust a diabetic's blood sugars automatically in an effort to keep them "in range," O'Neil tells investors in a research note. He believes Tandem is leading this revolution in conjunction with its partner, Dexcom (DXCM), and that it is in the early stages. The analyst recommends buying Tandem ahead of what he thinks will be the "next big run" in the stock. O'Neil keeps a Buy rating on the name with a $60 price target.
10/01/18
PIPR
10/01/18
NO CHANGE
PIPR
Overweight
Abbott news a negative headline for DexCom, says Piper Jaffray
Abbott Laboratories (ABT) this morning announced CE Mark approval of Libre 2, which provides optional real-time alarms at no additional cost compared to Libre 1, Piper Jaffray analyst JP McKim tells investors in a research note. From the analyst's understanding, users still have to scan the device for a reading but can have the system alert the user for hypo and/or hyper events customized by the user. Abbott is now one step closer to looking like a DexCom (DXCM), "though still not all the way there," McKim contends. Nonetheless, the analyst admits this morning's headline is a negative for DexCom. He still believes, however, that DexCom should continue to outpace consensus growth for several quarters. He keeps an Overweight rating on the shares. The stock in early trading is down 4%, or $5.78, to $137.26.
10/02/18
PIPR
10/02/18
NO CHANGE
PIPR
Overweight
Abbott's Libre sensor prices 'creeping higher,' says Piper Jaffray
Piper Jaffray analyst JP McKim noted that his tracking of the weekly price of Abbott's (ABT) FreeStyle Libre Sensors indicates that prices have risen over the last four weeks by varying amounts depending on the area of the country, but "no matter what area, prices have gone up." He reads this as evidence that the "aggressive pharmacy discounting" Abbott did in the early launch days are coming to an end and reiterates his previously communicated belief that CGM demand has hit an inflection point and that the market has room for multiple players, including both Abbott and DexCom (DXCM). McKim keeps an Overweight rating on DexCom shares.
MDT Medtronic
$98.51

-0.51 (-0.52%)

09/21/18
PIPR
09/21/18
NO CHANGE
Target $105
PIPR
Overweight
Medtronic acquisition of Mazor not a surprise, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien believes Medtronic's (MDT) $1.64B acquisition of Mazor Robotics (MZOR) is not much of a surprise given the companies' exclusive distribution arrangement and Medtronic's existing minority stake. The deal will help Medtronic's spine franchise business stay on the road to recovery, O'Brien tells investors in a research note. He keeps an Overweight rating on the shares with a $105 price target. Further, the analyst believes robot placements are "still in the early days" and that the acquisition will not "overly hurt" Globus Medical's (GMED) ability to sell systems in coming quarters. As such, O'Brien thinks the Mazor Robotics takeover will unlikely have an impact on Globus's Excelsius robot.
09/21/18
NEED
09/21/18
UPGRADE
NEED
Hold
Mazor Robotics upgraded to Hold from Underperform at Needham
Needham analyst Mike Matson upgraded Mazor Robotics (MZOR) to Hold from Underperform after its announced acquisition by Medtronic (MDT). The analyst notes that other bidders are unlikely to emerge given that Medtronic is "currently the exclusive global distributor of the Mazor X spinal robotics system" and already owns a significant part of the company. Matson adds that since the two companies do not compete in the same segment of the spine market, any anti-trust issues are unlikely to emerge in the regulatory review.
09/21/18
STFL
09/21/18
NO CHANGE
Target $70
STFL
Buy
IntriCon price target raised to $70 from $65 at Stifel
Stifel analyst Jonathan Block raised his price target on IntriCon (IIN) to $70 from $65 by assigning what he called "relatively conservative sales multiples" to his forecasts for the company's Medical and Hearing businesses, but he also contends that margin expansion will play an important part to IntriCon's story in the coming years, giving the stock a path toward $100 per share. Block, who believes IntriCon's traction with Medtronic (MDT) gives it a long runway for growth, keeps a Buy rating on the shares.
10/03/18
RBCM
10/03/18
NO CHANGE
Target $109
RBCM
Outperform
Medtronic price target raised to $109 from $104 at RBC Capital
RBC Capital analyst Glenn Novarro raised his price target on Medtronic to $109 and kept his Outperform rating following meetings with the company CEO and CFO. The analyst notes that the discussions were "upbeat" and reflected on the company's "track record of consistent financial performance" driven by "steady innovation and improved execution". Novarro added that the meetings increased his confidence in his FY19 revenue and earnings estimates with the company's growth drivers seen as "numerous" and diversified across its four business segments.
SENS Senseonics
$4.26

-0.11 (-2.52%)

06/22/18
CHLM
06/22/18
NO CHANGE
Target $6.5
CHLM
Buy
Senseonics 'cleared a major hurdle' with FDA approval, says Craig-Hallum
Craig-Hallum analyst Alexander Nowak reiterated a Buy rating and $6.50 price target on Senseonics after the company's premarket application for Eversense CGM system was approved by the FDA. In a research note to investors, Nowak said that while it was clear the market was expecting approval, the company "cleared a major hurdle" and sees shares continuing to rise as the company pivots from an early-stage company with approval risk to a commercial-stage company with execution risk. Nowak also noted that on an investor call on the FDA approval, the company confirmed that the Eversense U.S. label is consistent with the PMA application.
08/24/18
DOTC
08/24/18
INITIATION
Target $6
DOTC
Buy
Senseonics initiated with a Buy at Dougherty
Dougherty initiated Senseonics with a Buy and $6 price target.
06/22/18
ADAM
06/22/18
NO CHANGE
Target $6
ADAM
Buy
Senseonics FDA approval in time for major push at ADA, says Canaccord
Canaccord analyst Kyle Rose said the FDA approval of Senseonics' 90-day Eversense CGM system comes just in time for a major push at this year's ADA conference, which begins tomorrow. He noted the initial commercial team is in place for a U.S. launch and he hopes to get a pulse on the market's excitement at the conference for the upcoming launch. Rose reiterated his Buy rating and raised his price target to $6 from $5 on Senseonics shares.
06/11/18
CHLM
06/11/18
INITIATION
Target $6.5
CHLM
Buy
Senseonics initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Alexander Nowak started Senseonics with a Buy rating and $6.50 price target while noting that its novel continuous glucose monitor is nearing FDA approval and a largely untapped $23B market opportunity awaits.
TNDM TNDM

09/25/18
BARD
09/25/18
NO CHANGE
Target $47
BARD
Neutral
Baird not surprised by upside pre-announcement from Tandem Diabetes
After Tandem Diabetes pre-announced better than expected Q3 revenue and an updated full-year view that implies Q4 revenue largely in line with consensus estimates, Baird analyst Jeff Johnson said he was not surprised by the upside and expects the company's solid fundamentals to persist as U.S. growth remains strong and international revenue starts to contribute. However, he thinks the current valuation reflects this strength and maintains a Neutral rating and $47 price target on Tandem Diabetes shares.
09/26/18
CHLM
09/26/18
NO CHANGE
Target $59
CHLM
Buy
Tandem Diabetes price target raised to $59 from $52 at Craig-Hallum
Craig-Hallum analyst Alexander Nowak raised his price target for Tandem Diabetes to $59 from $52 after a "strong" investor event where the company beat Q3 sales estimates, raised 2018 guidance and announced solid long-term financial figures. Nowak argues that the analyst day confirms his thesis that the company with the best automation and most discreet pump will win, leading to market share gains and accelerated pump therapy penetration. He believes Tandem's story has just begun and is poised to morph into a much larger company as it executes on making diabetes therapy invisible. The analyst reiterates a Buy rating on the shares.
09/20/18
09/20/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Westport (WPRT) initiated with a Buy at H.C. Wainwright. 2. Legacy Reserves (LGCY) initiated with a Neutral at Seaport Global. 3. Tandem Diabetes (TNDM) initiated with a Buy at Craig-Hallum. 4. Bio-Rad (BIO) initiated with an Equal Weight at Morgan Stanley. 5. Brookfield (BAM) initiated with an Outperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/26/18
PIPR
09/26/18
NO CHANGE
Target $56
PIPR
Overweight
Tandem Diabetes price target raised to $56 from $32 at Piper Jaffray
Piper Jaffray analyst JP McKim raised his price target for Tandem Diabetes to $56 following the company's "positive" analyst day. The analyst has confidence in above average growth over the next 12 months and sees "lots of room" for estimates to go higher. The shares need to be owned during this "Goldilocks Period" where the company has the best closed loop system on the market, McKim tells investors in a research note. He reiterates an Overweight rating on Tandem Diabetes.
PODD Insulet
$100.00

-1.91 (-1.87%)

09/11/18
LEER
09/11/18
NO CHANGE
Target $130
LEER
Outperform
Insulet price target raised to $130 from $100 at Leerink
Leerink analyst Danielle Antalffy raised her price target for Insulet to $130 from $100 after the company announced that Patrick Sullivan would be stepping down as CEO at the end of this year, passing the baton to current COO Shacey Petrovic on January 1, 2019. The analyst believes this transition indicates that Insulet fundamentals are stronger than ever. In conjunction with the announcement, the company also reiterated full year 2018 sales guidance of $547M-$562M, she adds. Antalffy reiterates an Outperform rating on the shares.
09/05/18
OPCO
09/05/18
NO CHANGE
Target $54
OPCO
Outperform
Tandem Diabetes price target raised to $54 from $38 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised his price target for Tandem Diabetes (TNDM) to $54 from $38 on updated market estimates. The analyst notes that Medtronic's (MDT) recently reported Q1 diabetes results combined with the Q2 performances from Tandem as well as Insulet (PODD) suggests a strong underlying U.S. insulin pump market. Lichtman is raising his U.S. insulin market growth outlook from high-single digits to low-double digits in 2019/2020. He believes Tandem is well suited to capture the benefits of this acceleration given its pipeline. Lichtman reiterates an Outperform rating on Tandem's shares.
08/03/18
PIPR
08/03/18
NO CHANGE
Target $106
PIPR
Overweight
Insulet pullback on Q2 results should be short-lived, says Piper Jaffray
Insulet last night reported Q2 results below expectations and lowered guidance based on inventory issues internationally, whereby the prior distributor both returned goods and had plenty of inventory in the channel already, Piper Jaffray analyst JP McKim tells investors in a research note. The analyst says that while the news is disappointing, he's been fielding daily investor calls on the subject since late June, so this is not a total shock to the investment community. He believes management on the earnings call handled the issue very well and instilled confidence that it is under control. McKim suspects any share pullback will be short-lived and keeps an Overweight rating on Insulet with a $106 price target.
07/10/18
BMOC
07/10/18
NO CHANGE
Target $115
BMOC
Outperform
Insulet price target raised to $115 from $100 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Insulet to $115 while also adding the company to her Top Picks list as part of her broader Medical Technology: Mid-year View research note. The analyst notes that the company is "on the right side of a secular trend towards better diabetes management, with a full product pipeline, improved reimbursement, and marching rapidly towards cash flow break-even". Wuensch also kept her Outperform rating on Insulet.

TODAY'S FREE FLY STORIES

FSFG

First Savings Financial Group

$51.33

0.22 (0.43%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Hot Stocks
First Savings Financial raises quarterly dividend to 16c per share from 15c »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$110.97

1.5 (1.37%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Periodicals
Employees demand Microsoft cancel $480M U.S. Army contract, Reuters says »

Several Microsoft workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 01

    Mar

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 18

    Mar

ENT

Global Eagle

$2.66

(0.00%)

17:23
02/22/19
02/22
17:23
02/22/19
17:23
Hot Stocks
Global Eagle to cut workforce by roughly 15% »

As previously disclosed,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:15
02/22/19
02/22
17:15
02/22/19
17:15
General news
Breaking General news story  »

New York Federal Reserve…

NOC

Northrop Grumman

$288.84

2.54 (0.89%)

17:13
02/22/19
02/22
17:13
02/22/19
17:13
Hot Stocks
Northrop Grumman exec Kalan sells 4,312 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYB

LyondellBasell

$89.14

0.63 (0.71%)

17:07
02/22/19
02/22
17:07
02/22/19
17:07
Syndicate
Breaking Syndicate news story on LyondellBasell »

LyondellBasell files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCCO

Technical Comm Corp

$2.76

0.17 (6.56%)

17:06
02/22/19
02/22
17:06
02/22/19
17:06
Hot Stocks
Technical Comm Corp to submit plan to regain compliance with Nasdaq by March 4 »

Technical Comm Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFU

InfuSystem

$4.15

0.04 (0.97%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
InfuSystem announces settlement of derivative lawsuit »

InfuSystem Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALU

Kaiser Aluminum

$108.22

-1.9 (-1.73%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
Kaiser Aluminum names Neal West as new CFO »

Kaiser Aluminum announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDR

Alder Biopharmaceuticals

$14.35

0.19 (1.34%)

17:00
02/22/19
02/22
17:00
02/22/19
17:00
Hot Stocks
Alder Biopharmaceuticals submits eptinezumab BLA to FDA »

Alder BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

RF

Regions Financial

$16.24

-0.01 (-0.06%)

16:59
02/22/19
02/22
16:59
02/22/19
16:59
Syndicate
Breaking Syndicate news story on Regions Financial »

Regions Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

HL

Hecla Mining

$2.59

-0.145 (-5.31%)

16:58
02/22/19
02/22
16:58
02/22/19
16:58
Syndicate
Breaking Syndicate news story on Hecla Mining »

Hecla Mining files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

, CELG

Celgene

$89.15

0.54 (0.61%)

16:52
02/22/19
02/22
16:52
02/22/19
16:52
Hot Stocks
Bristol-Myers files proxy statement in connection with proposed Celgene merger »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

CELG

Celgene

$89.15

0.54 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 28

    Feb

  • 18

    May

  • 20

    May

  • 28

    May

TEN

Tenneco

$36.29

0.76 (2.14%)

16:48
02/22/19
02/22
16:48
02/22/19
16:48
Earnings
Tenneco sees FY19 revenue growth up 4%-5%, consensus $4.65B »

The company expects 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

TEN

Tenneco

$36.29

0.76 (2.14%)

16:46
02/22/19
02/22
16:46
02/22/19
16:46
Earnings
Tenneco reports preliminary Q4 revenue $4.3B, consensus $4.3B »

Sees FY18 EPS "near…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

XRX

Xerox

$31.50

0.16 (0.51%)

16:44
02/22/19
02/22
16:44
02/22/19
16:44
Conference/Events
Xerox management to meet with Loop Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

TWTR

Twitter

$31.70

0.94 (3.06%)

16:38
02/22/19
02/22
16:38
02/22/19
16:38
Hot Stocks
Twitter board member Evan Williams to step down at end of month »

On February 22, 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

ALLY

Ally Financial

$26.95

-0.07 (-0.26%)

16:34
02/22/19
02/22
16:34
02/22/19
16:34
Hot Stocks
Ally Financial CEO sells over 97,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Mar

  • 28

    May

DAL

Delta Air Lines

$51.52

0.04 (0.08%)

16:33
02/22/19
02/22
16:33
02/22/19
16:33
Hot Stocks
Delta Air Lines' West sells 36,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REN

Resolute Energy

$31.61

0.09 (0.29%)

16:30
02/22/19
02/22
16:30
02/22/19
16:30
Hot Stocks
Resolute Energy stockholders approve merger with Cimarex Energy »

Resolute Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

16:30
02/22/19
02/22
16:30
02/22/19
16:30
Options
Preliminary option volume of 18.8M today »

Preliminary option volume…

ORI

Old Republic

$21.14

0.04 (0.19%)

16:22
02/22/19
02/22
16:22
02/22/19
16:22
Hot Stocks
Old Republic raises quarterly dividend to 20c from 19.5c per share »

This dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
02/22/19
02/22
16:20
02/22/19
16:20
Options
Closing CBOE SPX and VIX Index summary for February 22nd »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
02/22/19
02/22
16:17
02/22/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFC

Ellington Financial

$16.97

-0.01 (-0.06%)

16:16
02/22/19
02/22
16:16
02/22/19
16:16
Hot Stocks
Ellington Financial to convert to a Delaware corporation »

Ellington Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.